Dr Randeep Guleria AIIMS Delhi Director today said that Bharat Biotech’s Covaxin vaccine’s data for children aged 2-17 years after completion of the Phase 2/3 trials should be available by September and the approval should be expected in the same month. He added that if Pfizer’s vaccine also comes to India then that could also be an option for children.
